EntryPoint Capital LLC Invests $299,000 in Delcath Systems, Inc. (NASDAQ:DCTH)

EntryPoint Capital LLC acquired a new position in Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 24,816 shares of the company's stock, valued at approximately $299,000. EntryPoint Capital LLC owned approximately 0.08% of Delcath Systems at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of DCTH. Point72 Asia Singapore Pte. Ltd. bought a new stake in Delcath Systems during the third quarter valued at about $102,000. Polar Asset Management Partners Inc. bought a new position in shares of Delcath Systems during the 3rd quarter valued at approximately $1,594,000. State Street Corp increased its holdings in Delcath Systems by 12.4% in the 3rd quarter. State Street Corp now owns 85,457 shares of the company's stock worth $772,000 after acquiring an additional 9,400 shares in the last quarter. Jane Street Group LLC bought a new stake in Delcath Systems during the 3rd quarter worth approximately $110,000. Finally, Barclays PLC bought a new stake in Delcath Systems during the 3rd quarter worth approximately $104,000. 61.12% of the stock is owned by institutional investors.

Delcath Systems Stock Performance

DCTH traded down $0.16 during trading on Tuesday, reaching $12.57. 639,191 shares of the company traded hands, compared to its average volume of 341,273. The company has a market cap of $419.88 million, a P/E ratio of -9.31 and a beta of 0.82. Delcath Systems, Inc. has a 12-month low of $4.26 and a 12-month high of $16.97. The firm has a fifty day simple moving average of $14.51 and a 200 day simple moving average of $12.09.

Remove Ads

Delcath Systems (NASDAQ:DCTH - Get Free Report) last issued its earnings results on Thursday, March 6th. The company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). The company had revenue of $15.10 million for the quarter, compared to the consensus estimate of $14.96 million. Delcath Systems had a negative return on equity of 338.16% and a negative net margin of 150.70%. During the same quarter in the prior year, the company posted ($0.48) EPS. As a group, sell-side analysts expect that Delcath Systems, Inc. will post -0.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on DCTH shares. Craig Hallum increased their price objective on shares of Delcath Systems from $18.00 to $21.00 and gave the stock a "buy" rating in a research note on Friday, January 17th. HC Wainwright upped their target price on shares of Delcath Systems from $22.00 to $24.00 and gave the stock a "buy" rating in a report on Friday, March 7th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Delcath Systems presently has a consensus rating of "Moderate Buy" and a consensus target price of $22.75.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.